Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
NVDA 4.45EWJ 2.89TECK.B.TO 5.26CNQ.TO -0.07HHL.TO 0.035SYLD 1.14HAC.TO 0.14TRU -2.15
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

26.17
+0.57 (2.23%)
as of Jun 11, 2026, 8:00:00 pm Market Open.
322 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Pfizer Inc(PFE)

Jan 11, 2021
It has an interesting problem. It has the solution to COVID-19 and they have orders for billions of doses but the stock has not done anything. The earnings forecast for the company are going sideways. Analysts probably think the demand for COVID vaccines will decline sharply when COVID is over and then there will be all these plants that are idle. So looking longer term, they see the earnings as flat.
Photo of Ross HealyRoss HealyUnlock Rating
$37.65

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Pfizer Inc(PFE)

Dec 29, 2020

A core name, but it's hard for big pharma names like this to find a product to drive growth. He prefers biotechs which offer better growth, even ETFs like IBB.

Photo of John ZechnerJohn Zechner
No
Unlock Rating
$36.98

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 14, 2020

PFE-N vs. MRNA-Q. PFE-N is a much, much larger company. MRNA-Q is bringing their first product ever to market. PFE-N is well established and their vaccine is one of many products. They also have many drugs going off patent but their pipeline is looking better. PFE-N is not one of her core holdings but their earnings growth should improve over time.

Photo of Christine PooleChristine Poole
No
Unlock Rating
$39.51

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Dec 08, 2020
(A Top Pick Sep 24/20, Up 17.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE has achieved its $42 target. To be disciplined, we are recommending covering 50% of the position. We are also recommending to trail up the stop to $33.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$42.24

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Nov 23, 2020
He sold it about two weeks ago when they put out the vaccine news. He was looking to trim or sell anyway. They are going through the spin-off of their generic business (UpJohn). He does not think the vaccine will be a long term driver on their financials. They had a miss in their oncology program back in June that impacted the long term growth rate going forward.
Photo of Jamie Murray Jamie Murray
No
Unlock Rating
$36.52

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 19, 2020
The positive vaccine news helped the stock rally but it has since given up the gains. There is not as much growth as you would like, and pay 13x earnings. Likes other names that has better growth. It has been moving sideways. The only reason to own it is for the dividend.
Photo of Stan WongStan Wong
No
Unlock Rating
$36.11

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 27, 2020
Allan Tong’s Discover Picks The divvy pays nearly 4%. Investors are already pushing up the Pfizer stock near 52-week highs and price target, both $41, though it trades at a PE of only 14.9x. Currently, one analyst rates Pfizer stock a strong buy, 11 more a buy, nine a hold, and one a sell, its strongest recommendations so far this year. It's a strong company, but upside may be limited. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.
Photo of Stockchase DiscoverStockchase Discover
Owned
Unlock Rating
$37.43

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Oct 20, 2020
Tough to analyze now. He's awaiting their drug test results. They're in the middle of spinning off long-life assets, including Viagra (later this year or next). This spinning-off will transform Pfizer from boring long-life assets to focus on R&D drugs. He expects their Covid vaccine to succeed the first. The CEO issued an update Friday and the testing data so far looks promising. There haven't been any adverse test results yet. He expects data in 2-5 weeks. He's closely watching this. Their Covid vaccine will be a catalyst short-term.
Photo of Paul MacDonaldPaul MacDonaldUnlock Rating
$37.58

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Pfizer Inc(PFE)

Oct 14, 2020
Likes healthcare because of demographics, but not her preference. In the process of building up their pipeline. Revenue portfolio will have another period of patent expiration. Wants to see more visibility on the pipeline, or perhaps an acquisition.
Photo of Christine PooleChristine Poole
No
Unlock Rating
$36.86

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Pfizer Inc(PFE)

Sep 24, 2020
Stochchase Research Editor: Michael O'Reilly PFE is a defensive Top Pick that pays a strong yield, with history of dividend growth and a strong balance sheet. It is one of the world's leading pharmaceutical companies with a robust pipeline of new products in development (targeting 25 new drugs to market by 2025). They are partnering to develop a COVID-19 vaccine that is now in stage 2/3 testing and has a contract with the US government for $1.95 billion for the first 100 million doses if successful. The company holds $1.8 billion in cash reserves. The yield is strong and is supported with a 58% payout ratio. We would buy this using a $31 stop-loss, looking for a return towards $42. Yield 4.22% (Analysts’ price target is $41.79)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$35.68

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 15, 2020
Pfizer is having an analysts day this week. She owns another large pharma (see today's top picks). All the pharmas have said they won't make a lot of money on the vaccine in the first phase at least. They're still building a pipeline of drugs, so she doesn't own it.
Photo of Christine PooleChristine Poole
No
Unlock Rating
$37.05

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 14, 2020
It's a bond with drugs. It doesn't have the pipeline of drugs to attract investors.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$37.01

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 04, 2020
One of the largest pharma companies in the world. They have done a good job rebuilding their pipeline of drugs. It's now better built with constant new products. They took a hit due to a cancer drug that didn't prove itself. You get a nice dividend. In the medical space, there are other names like Boston Scientific that could be a good alternative.
Photo of Jamie Murray Jamie Murray
Owned
Unlock Rating
$36.36

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 27, 2020

PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

Photo of Gordon ReidGordon ReidUnlock Rating
$37.81

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 24, 2020
(A Top Pick Sep 16/19, Down 9%) He bought it for stability and the dividend. They have new drugs, including a COVID one. Pays a solid 3.8% dividend. Not worried about this.
Photo of Bruce MurrayBruce Murray
Owned
Unlock Rating
$38.65

Stock price when the opinion was issued

$26.17

As of Jun 11, 2026. Market Open.

biotechnologypharmaceutical
Showing 106 to 120 of 801 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VEEV -2.21$161.55
WSP.TO 0.31$183.77
VRTX 9.33$445.04
OTEX.TO 0.24$30.52
CCO.TO 5.6$138.04

Today's Top Picks

NVDA 4.45$204.87
EWJ 2.89$92.18
TECK.B.T… 5.26$88.81
CNQ.TO -0.07$63.52
HHL.TO 0.035$6.945

Popular Articles

Latest Sell Signals

TD.TO 2.57$162.22
MBLY 0.44$9.58
ASAN -0.12$7.46
MODG 0.53$16.79
NVTS 1.71$22.21

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Brian Acker, CA

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica